{
"info": {
"nct_id": "NCT02124148",
"official_title": "A Phase 1b Trial of LY2606368 in Combination With Chemotherapy or Targeted Agents in Advanced and/or Metastatic Tumors",
"inclusion_criteria": "* Must be appropriate candidate for experimental therapy, as determined by investigator, after available standard therapies have failed\n* Have adequate organ function\n* Prior Therapies: Systemic treatments: must have discontinued previous systemic treatments for cancer and recovered from the acute effects of therapy. Participants must have discontinued mitomycin-C or nitrosourea therapy at least 42 days and have discontinued any cytotoxic therapies at least 28 days prior to study enrollment. Radiation therapy and surgery: must be completed at least 4 weeks before study enrollment\n* All parts except Part B, Part E2, and Part E3 dose expansion: Must have diagnosis of cancer that is advanced or metastatic\n* Part B dose expansion: Must have confirmed Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type colorectal cancer that is metastatic or recurrent and has failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant of irinotecan or oxaliplatin\n* Part E2 dose expansion: must have cancer that is advanced or metastatic and have prior documentation of a mutation of PIK3CA\n* Part E3 dose expansion: must have advanced or metastatic ER-negative, PR-negative, and HER-2 non-overexpressing breast cancer\n* Must be available during the duration of the study and willing to follow the study procedures\n* Parts A and B: If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for six months following the last dose of study drug\n* Parts C, D and E: If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for three months following the last dose of study drug\n* If the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within 14 days of the first dose of study drug and must not be breast feeding\n* Part E: Are able to swallow capsules or tablets\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Have received more than 2 previous lines of cytotoxic chemotherapy (if receiving cisplatin, 5-FU or pemetrexed)\n* Must not have taken an unapproved drug as treatment for any indication within the last 28 days prior to starting study treatment\n* Must not have an active symptomatic fungal, bacterial or viral infection, including human immunodeficiency virus (HIV) or Hepatitis A, B, or C\n* Must not have a serious heart condition, such as congestive heart failure, unstable angina pectoris, or heart attack within the last three months\n* Must not have a family history of long QTc syndrome\n* Must not have a serotonin-secreting carcinoid tumor or a prior history of drug-induced serotonin syndrome\n* Must not have acute leukemia\n* Part E: Have insulin-dependent (type I) diabetes or a history of gestational diabetes\n* Part E: Prior treatment with a PI3K/mTOR inhibitor",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"identified_line": {
"line": "* Must be appropriate candidate for experimental therapy, as determined by investigator, after available standard therapies have failed",
"criterions": [
{
"exact_snippets": "appropriate candidate for experimental therapy",
"criterion": "candidate for experimental therapy",
"requirement": {
"requirement_type": "appropriateness",
"expected_value": true
}
},
{
"exact_snippets": "available standard therapies have failed",
"criterion": "standard therapies",
"requirement": {
"requirement_type": "status",
"expected_value": "failed"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"condition": {
"exact_snippets": "available standard therapies have failed",
"criterion": "standard therapies",
"requirement": {
"requirement_type": "status",
"expected_value": "failed"
}
},
"then_criteria": {
"exact_snippets": "appropriate candidate for experimental therapy",
"criterion": "candidate for experimental therapy",
"requirement": {
"requirement_type": "appropriateness",
"expected_value": true
}
},
"else_criteria": null
}
]
}
},
{
"identified_line": {
"line": "* Have adequate organ function",
"criterions": [
{
"exact_snippets": "adequate organ function",
"criterion": "organ function",
"requirement": {
"requirement_type": "adequacy",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "adequate organ function",
"criterion": "organ function",
"requirement": {
"requirement_type": "adequacy",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* Prior Therapies: Systemic treatments: must have discontinued previous systemic treatments for cancer and recovered from the acute effects of therapy. Participants must have discontinued mitomycin-C or nitrosourea therapy at least 42 days and have discontinued any cytotoxic therapies at least 28 days prior to study enrollment. Radiation therapy and surgery: must be completed at least 4 weeks before study enrollment",
"criterions": [
{
"exact_snippets": "must have discontinued previous systemic treatments for cancer",
"criterion": "discontinuation of previous systemic treatments",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "recovered from the acute effects of therapy",
"criterion": "recovery from acute effects of therapy",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "discontinued mitomycin-C or nitrosourea therapy at least 42 days",
"criterion": "discontinuation of mitomycin-C or nitrosourea therapy",
"requirement": {
"requirement_type": "time since discontinuation",
"expected_value": {
"operator": ">=",
"value": 42,
"unit": "days"
}
}
},
{
"exact_snippets": "discontinued any cytotoxic therapies at least 28 days prior to study enrollment",
"criterion": "discontinuation of cytotoxic therapies",
"requirement": {
"requirement_type": "time since discontinuation",
"expected_value": {
"operator": ">=",
"value": 28,
"unit": "days"
}
}
},
{
"exact_snippets": "Radiation therapy and surgery: must be completed at least 4 weeks before study enrollment",
"criterion": "completion of radiation therapy and surgery",
"requirement": {
"requirement_type": "time since completion",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "must have discontinued previous systemic treatments for cancer",
"criterion": "discontinuation of previous systemic treatments",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "recovered from the acute effects of therapy",
"criterion": "recovery from acute effects of therapy",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "discontinued mitomycin-C or nitrosourea therapy at least 42 days",
"criterion": "discontinuation of mitomycin-C or nitrosourea therapy",
"requirement": {
"requirement_type": "time since discontinuation",
"expected_value": {
"operator": ">=",
"value": 42,
"unit": "days"
}
}
},
{
"exact_snippets": "discontinued any cytotoxic therapies at least 28 days prior to study enrollment",
"criterion": "discontinuation of cytotoxic therapies",
"requirement": {
"requirement_type": "time since discontinuation",
"expected_value": {
"operator": ">=",
"value": 28,
"unit": "days"
}
}
}
]
},
{
"exact_snippets": "Radiation therapy and surgery: must be completed at least 4 weeks before study enrollment",
"criterion": "completion of radiation therapy and surgery",
"requirement": {
"requirement_type": "time since completion",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
}
]
}
},
{
"identified_line": {
"line": "* All parts except Part B, Part E2, and Part E3 dose expansion: Must have diagnosis of cancer that is advanced or metastatic",
"criterions": [
{
"exact_snippets": "diagnosis of cancer that is advanced or metastatic",
"criterion": "cancer diagnosis",
"requirement": {
"requirement_type": "stage",
"expected_value": [
"advanced",
"metastatic"
]
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"not_criteria": {
"and_criteria": [
{
"exact_snippets": "Part B",
"criterion": "trial part",
"requirement": {
"requirement_type": "exclusion",
"expected_value": "Part B"
}
},
{
"exact_snippets": "Part E2",
"criterion": "trial part",
"requirement": {
"requirement_type": "exclusion",
"expected_value": "Part E2"
}
},
{
"exact_snippets": "Part E3",
"criterion": "trial part",
"requirement": {
"requirement_type": "exclusion",
"expected_value": "Part E3"
}
}
]
}
}
]
},
{
"exact_snippets": "diagnosis of cancer that is advanced or metastatic",
"criterion": "cancer diagnosis",
"requirement": {
"requirement_type": "stage",
"expected_value": [
"advanced",
"metastatic"
]
}
}
]
}
},
{
"identified_line": {
"line": "* Part B dose expansion: Must have confirmed Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type colorectal cancer that is metastatic or recurrent and has failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant of irinotecan or oxaliplatin",
"criterions": [
{
"exact_snippets": "confirmed Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type colorectal cancer",
"criterion": "KRAS status",
"requirement": {
"requirement_type": "status",
"expected_value": "wild-type"
}
},
{
"exact_snippets": "colorectal cancer that is metastatic or recurrent",
"criterion": "colorectal cancer",
"requirement": {
"requirement_type": "status",
"expected_value": [
"metastatic",
"recurrent"
]
}
},
{
"exact_snippets": "failed oxaliplatin- and irinotecan-based chemotherapy",
"criterion": "chemotherapy response",
"requirement": {
"requirement_type": "response",
"expected_value": "failed"
}
},
{
"exact_snippets": "intolerant of irinotecan or oxaliplatin",
"criterion": "chemotherapy tolerance",
"requirement": {
"requirement_type": "tolerance",
"expected_value": "intolerant"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "confirmed Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type colorectal cancer",
"criterion": "KRAS status",
"requirement": {
"requirement_type": "status",
"expected_value": "wild-type"
}
},
{
"exact_snippets": "colorectal cancer that is metastatic or recurrent",
"criterion": "colorectal cancer",
"requirement": {
"requirement_type": "status",
"expected_value": [
"metastatic",
"recurrent"
]
}
}
]
},
{
"or_criteria": [
{
"exact_snippets": "failed oxaliplatin- and irinotecan-based chemotherapy",
"criterion": "chemotherapy response",
"requirement": {
"requirement_type": "response",
"expected_value": "failed"
}
},
{
"exact_snippets": "intolerant of irinotecan or oxaliplatin",
"criterion": "chemotherapy tolerance",
"requirement": {
"requirement_type": "tolerance",
"expected_value": "intolerant"
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Part E2 dose expansion: must have cancer that is advanced or metastatic and have prior documentation of a mutation of PIK3CA",
"criterions": [
{
"exact_snippets": "must have cancer that is advanced or metastatic",
"criterion": "cancer stage",
"requirement": {
"requirement_type": "stage",
"expected_value": [
"advanced",
"metastatic"
]
}
},
{
"exact_snippets": "prior documentation of a mutation of PIK3CA",
"criterion": "PIK3CA mutation",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"or_criteria": [
{
"exact_snippets": "must have cancer that is advanced or metastatic",
"criterion": "cancer stage",
"requirement": {
"requirement_type": "stage",
"expected_value": [
"advanced",
"metastatic"
]
}
}
]
},
{
"exact_snippets": "prior documentation of a mutation of PIK3CA",
"criterion": "PIK3CA mutation",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* Must be available during the duration of the study and willing to follow the study procedures",
"criterions": [
{
"exact_snippets": "Must be available during the duration of the study",
"criterion": "availability during study",
"requirement": {
"requirement_type": "availability",
"expected_value": true
}
},
{
"exact_snippets": "willing to follow the study procedures",
"criterion": "willingness to follow study procedures",
"requirement": {
"requirement_type": "willingness",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Must be available during the duration of the study",
"criterion": "availability during study",
"requirement": {
"requirement_type": "availability",
"expected_value": true
}
},
{
"exact_snippets": "willing to follow the study procedures",
"criterion": "willingness to follow study procedures",
"requirement": {
"requirement_type": "willingness",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* Parts A and B: If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for six months following the last dose of study drug",
"criterions": [
{
"exact_snippets": "participant is of reproductive potential",
"criterion": "reproductive potential",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "must agree to use medically approved contraceptive precautions",
"criterion": "use of contraceptive precautions",
"requirement": {
"requirement_type": "agreement",
"expected_value": true
}
},
{
"exact_snippets": "during the study and for six months following the last dose of study drug",
"criterion": "duration of contraceptive use",
"requirement": {
"requirement_type": "duration",
"expected_value": "during the study and for six months following the last dose of study drug"
}
}
]
},
"logical_structure": {
"condition": {
"exact_snippets": "participant is of reproductive potential",
"criterion": "reproductive potential",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
"then_criteria": {
"and_criteria": [
{
"exact_snippets": "must agree to use medically approved contraceptive precautions",
"criterion": "use of contraceptive precautions",
"requirement": {
"requirement_type": "agreement",
"expected_value": true
}
},
{
"exact_snippets": "during the study and for six months following the last dose of study drug",
"criterion": "duration of contraceptive use",
"requirement": {
"requirement_type": "duration",
"expected_value": "during the study and for six months following the last dose of study drug"
}
}
]
},
"else_criteria": null
}
},
{
"identified_line": {
"line": "* Parts C, D and E: If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for three months following the last dose of study drug",
"criterions": [
{
"exact_snippets": "participant is of reproductive potential",
"criterion": "reproductive potential",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "must agree to use medically approved contraceptive precautions",
"criterion": "use of contraceptive precautions",
"requirement": {
"requirement_type": "agreement",
"expected_value": true
}
},
{
"exact_snippets": "during the study and for three months following the last dose of study drug",
"criterion": "duration of contraceptive use",
"requirement": {
"requirement_type": "duration",
"expected_value": "during the study and for three months following the last dose of study drug"
}
}
]
},
"logical_structure": {
"condition": {
"exact_snippets": "participant is of reproductive potential",
"criterion": "reproductive potential",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
"then_criteria": {
"and_criteria": [
{
"exact_snippets": "must agree to use medically approved contraceptive precautions",
"criterion": "use of contraceptive precautions",
"requirement": {
"requirement_type": "agreement",
"expected_value": true
}
},
{
"exact_snippets": "during the study and for three months following the last dose of study drug",
"criterion": "duration of contraceptive use",
"requirement": {
"requirement_type": "duration",
"expected_value": "during the study and for three months following the last dose of study drug"
}
}
]
},
"else_criteria": null
}
},
{
"identified_line": {
"line": "* If the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within 14 days of the first dose of study drug and must not be breast feeding",
"criterions": [
{
"exact_snippets": "female of childbearing potential",
"criterion": "gender and reproductive status",
"requirement": {
"requirement_type": "gender",
"expected_value": "female"
}
},
{
"exact_snippets": "female of childbearing potential",
"criterion": "gender and reproductive status",
"requirement": {
"requirement_type": "reproductive status",
"expected_value": "childbearing potential"
}
},
{
"exact_snippets": "negative serum or urine pregnancy test within 14 days of the first dose of study drug",
"criterion": "pregnancy test",
"requirement": {
"requirement_type": "result",
"expected_value": "negative"
}
},
{
"exact_snippets": "negative serum or urine pregnancy test within 14 days of the first dose of study drug",
"criterion": "pregnancy test",
"requirement": {
"requirement_type": "timing",
"expected_value": "within 14 days of the first dose of study drug"
}
},
{
"exact_snippets": "must not be breast feeding",
"criterion": "breastfeeding status",
"requirement": {
"requirement_type": "status",
"expected_value": false
}
}
]
},
"logical_structure": {
"condition": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "female of childbearing potential",
"criterion": "gender and reproductive status",
"requirement": {
"requirement_type": "gender",
"expected_value": "female"
}
},
{
"exact_snippets": "female of childbearing potential",
"criterion": "gender and reproductive status",
"requirement": {
"requirement_type": "reproductive status",
"expected_value": "childbearing potential"
}
}
]
}
]
},
"then_criteria": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "negative serum or urine pregnancy test within 14 days of the first dose of study drug",
"criterion": "pregnancy test",
"requirement": {
"requirement_type": "result",
"expected_value": "negative"
}
},
{
"exact_snippets": "negative serum or urine pregnancy test within 14 days of the first dose of study drug",
"criterion": "pregnancy test",
"requirement": {
"requirement_type": "timing",
"expected_value": "within 14 days of the first dose of study drug"
}
}
]
},
{
"exact_snippets": "must not be breast feeding",
"criterion": "breastfeeding status",
"requirement": {
"requirement_type": "status",
"expected_value": false
}
}
]
},
"else_criteria": null
}
},
{
"identified_line": {
"line": "* Part E: Are able to swallow capsules or tablets",
"criterions": [
{
"exact_snippets": "able to swallow capsules or tablets",
"criterion": "ability to swallow capsules or tablets",
"requirement": {
"requirement_type": "ability",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "able to swallow capsules or tablets",
"criterion": "ability to swallow capsules or tablets",
"requirement": {
"requirement_type": "ability",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
}
},
{
"identified_line": {
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
}
}
],
"exclusion_lines": [
{
"identified_line": {
"line": "* Have received more than 2 previous lines of cytotoxic chemotherapy (if receiving cisplatin, 5-FU or pemetrexed)",
"criterions": [
{
"exact_snippets": "Have received more than 2 previous lines of cytotoxic chemotherapy",
"criterion": "previous lines of cytotoxic chemotherapy",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": ">",
"value": 2,
"unit": "lines"
}
}
},
{
"exact_snippets": "if receiving cisplatin, 5-FU or pemetrexed",
"criterion": "current chemotherapy drugs",
"requirement": {
"requirement_type": "presence",
"expected_value": [
"cisplatin",
"5-FU",
"pemetrexed"
]
}
}
]
},
"logical_structure": {
"condition": {
"exact_snippets": "if receiving cisplatin, 5-FU or pemetrexed",
"criterion": "current chemotherapy drugs",
"requirement": {
"requirement_type": "presence",
"expected_value": [
"cisplatin",
"5-FU",
"pemetrexed"
]
}
},
"then_criteria": {
"exact_snippets": "Have received more than 2 previous lines of cytotoxic chemotherapy",
"criterion": "previous lines of cytotoxic chemotherapy",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": ">",
"value": 2,
"unit": "lines"
}
}
},
"else_criteria": null
}
},
{
"identified_line": {
"line": "* Must not have taken an unapproved drug as treatment for any indication within the last 28 days prior to starting study treatment",
"criterions": [
{
"exact_snippets": "Must not have taken an unapproved drug as treatment for any indication within the last 28 days",
"criterion": "unapproved drug use",
"requirement": {
"requirement_type": "time since last use",
"expected_value": {
"operator": ">=",
"value": 28,
"unit": "days"
}
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "Must not have taken an unapproved drug as treatment for any indication within the last 28 days",
"criterion": "unapproved drug use",
"requirement": {
"requirement_type": "time since last use",
"expected_value": {
"operator": ">=",
"value": 28,
"unit": "days"
}
}
}
}
},
{
"identified_line": {
"line": "* Must not have an active symptomatic fungal, bacterial or viral infection, including human immunodeficiency virus (HIV) or Hepatitis A, B, or C",
"criterions": [
{
"exact_snippets": "active symptomatic fungal, bacterial or viral infection",
"criterion": "active symptomatic infection",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "human immunodeficiency virus (HIV)",
"criterion": "HIV infection",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "Hepatitis A, B, or C",
"criterion": "Hepatitis infection",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "active symptomatic fungal, bacterial or viral infection",
"criterion": "active symptomatic infection",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"or_criteria": [
{
"exact_snippets": "human immunodeficiency virus (HIV)",
"criterion": "HIV infection",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "Hepatitis A, B, or C",
"criterion": "Hepatitis infection",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
]
}
]
}
]
}
},
{
"identified_line": {
"line": "* Must not have a serious heart condition, such as congestive heart failure, unstable angina pectoris, or heart attack within the last three months",
"criterions": [
{
"exact_snippets": "serious heart condition",
"criterion": "serious heart condition",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "congestive heart failure",
"criterion": "congestive heart failure",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "unstable angina pectoris",
"criterion": "unstable angina pectoris",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "heart attack within the last three months",
"criterion": "heart attack",
"requirement": {
"requirement_type": "time since event",
"expected_value": {
"operator": ">",
"value": 3,
"unit": "months"
}
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "serious heart condition",
"criterion": "serious heart condition",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"or_criteria": [
{
"exact_snippets": "congestive heart failure",
"criterion": "congestive heart failure",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "unstable angina pectoris",
"criterion": "unstable angina pectoris",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "heart attack within the last three months",
"criterion": "heart attack",
"requirement": {
"requirement_type": "time since event",
"expected_value": {
"operator": ">",
"value": 3,
"unit": "months"
}
}
}
]
}
]
}
]
}
},
{
"identified_line": {
"line": "* Must not have a family history of long QTc syndrome",
"criterions": [
{
"exact_snippets": "family history of long QTc syndrome",
"criterion": "family history of long QTc syndrome",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "family history of long QTc syndrome",
"criterion": "family history of long QTc syndrome",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
}
},
{
"identified_line": {
"line": "* Must not have a serotonin-secreting carcinoid tumor or a prior history of drug-induced serotonin syndrome",
"criterions": [
{
"exact_snippets": "Must not have a serotonin-secreting carcinoid tumor",
"criterion": "serotonin-secreting carcinoid tumor",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "prior history of drug-induced serotonin syndrome",
"criterion": "drug-induced serotonin syndrome",
"requirement": {
"requirement_type": "history",
"expected_value": false
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "Must not have a serotonin-secreting carcinoid tumor",
"criterion": "serotonin-secreting carcinoid tumor",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "prior history of drug-induced serotonin syndrome",
"criterion": "drug-induced serotonin syndrome",
"requirement": {
"requirement_type": "history",
"expected_value": false
}
}
]
}
},
{
"identified_line": {
"line": "* Must not have acute leukemia",
"criterions": [
{
"exact_snippets": "Must not have acute leukemia",
"criterion": "acute leukemia",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Must not have acute leukemia",
"criterion": "acute leukemia",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
]
}
},
{
"identified_line": {
"line": "* Part E: Have insulin-dependent (type I) diabetes or a history of gestational diabetes",
"criterions": [
{
"exact_snippets": "insulin-dependent (type I) diabetes",
"criterion": "type I diabetes",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "history of gestational diabetes",
"criterion": "gestational diabetes",
"requirement": {
"requirement_type": "history",
"expected_value": true
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "insulin-dependent (type I) diabetes",
"criterion": "type I diabetes",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "history of gestational diabetes",
"criterion": "gestational diabetes",
"requirement": {
"requirement_type": "history",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* Part E: Prior treatment with a PI3K/mTOR inhibitor",
"criterions": [
{
"exact_snippets": "Prior treatment with a PI3K/mTOR inhibitor",
"criterion": "PI3K/mTOR inhibitor treatment",
"requirement": {
"requirement_type": "prior treatment",
"expected_value": true
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "Prior treatment with a PI3K/mTOR inhibitor",
"criterion": "PI3K/mTOR inhibitor treatment",
"requirement": {
"requirement_type": "prior treatment",
"expected_value": true
}
}
}
}
],
"miscellaneous_lines": [],
"failed_inclusion": [
{
"identified_line": {
"line": "* Part E3 dose expansion: must have advanced or metastatic ER-negative, PR-negative, and HER-2 non-overexpressing breast cancer",
"criterions": [
{
"exact_snippets": "advanced or metastatic ER-negative, PR-negative, and HER-2 non-overexpressing breast cancer",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "stage",
"expected_value": [
"advanced",
"metastatic"
]
}
},
{
"exact_snippets": "advanced or metastatic ER-negative, PR-negative, and HER-2 non-overexpressing breast cancer",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "ER status",
"expected_value": "negative"
}
},
{
"exact_snippets": "advanced or metastatic ER-negative, PR-negative, and HER-2 non-overexpressing breast cancer",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "PR status",
"expected_value": "negative"
}
},
{
"exact_snippets": "advanced or metastatic ER-negative, PR-negative, and HER-2 non-overexpressing breast cancer",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "HER-2 expression",
"expected_value": "non-overexpressing"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"or_criteria": [
{
"exact_snippets": "advanced or metastatic ER-negative, PR-negative, and HER-2 non-overexpressing breast cancer",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "stage",
"expected_value": "advanced"
}
},
{
"exact_snippets": "advanced or metastatic ER-negative, PR-negative, and HER-2 non-overexpressing breast cancer",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "stage",
"expected_value": "metastatic"
}
}
]
},
{
"exact_snippets": "advanced or metastatic ER-negative, PR-negative, and HER-2 non-overexpressing breast cancer",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "ER status",
"expected_value": "negative"
}
},
{
"exact_snippets": "advanced or metastatic ER-negative, PR-negative, and HER-2 non-overexpressing breast cancer",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "PR status",
"expected_value": "negative"
}
},
{
"exact_snippets": "advanced or metastatic ER-negative, PR-negative, and HER-2 non-overexpressing breast cancer",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "HER-2 expression",
"expected_value": "non-overexpressing"
}
}
]
}
}
],
"failed_exclusion": [],
"failed_miscellaneous": []
}